Home / Resources / Protecting Data in Clinical Trial Disclosure: Best Practices in Personal Data Anonymization

Protecting Data in Clinical Trial Disclosure: Best Practices in Personal Data Anonymization

Article

薬事規制関連支援サービス

NOV 22, 2023

The reflection here is whether the level of anonymization affects the utility of the data being submitted, so not a re-identification risk, but rather one concerning the viability and usefulness of the data as a result of an anonymization.

Peter Vine, Head of Privacy at Norstella

Related products

Automated submissions to Clinical Trials

TrialScope Disclose

臨床試験情報開示の管理において最も広く信頼されているソリューション

Pink Sheet

世界の薬事規制動向＆情報に特化したニュースサービス

TrialScope Intelligence

国際的な臨床試験情報開示のコンプライアンスに必要な重要な規制知識を一元化した対話型のリポジトリ

Related resources

Professionals analyzing data trends on digital devices.

DEC 07, 2023

Article

薬事規制関連支援サービス

Understanding Biopharma Regulation

Selected articles on Clinical Trials policy and from Pink Sheet’s analyses of Trends and Regulatory Data. Know when new clinical trial approaches are validated for regulators and how regulators are applying product review policies to specific types of products.

Clinical Docs for CTIS Submission-resource-card-thumbnail

AUG 22, 2023

Whitepaper

薬事規制関連支援サービス

Clinical Documents for CTIS Submission: Navigating the Privacy Tightrope

This white paper examines the challenges, potential risks, best practices, and future trends related to anonymizing personal data for CTIS submissions.

Disclosure as a Service Case Study resource card thumbnail

DEC 01, 2019

サービス活用事例

薬事規制関連支援サービス

Small But Growing Biotech Manages Disclosure, Maintains Compliance, & Keeps Its Promise to Patients

While most large study sponsors place a high priority on transparency, smaller sponsors are not as quick to jump on the bandwagon. This one’s an exception.

View all resources